OBJECTIVE: To compare the performance of the Focus HerpeSelect-2 enzyme immunoassay (EIA) with the gold standard herpes simplex virus (HSV) type 2 western blot, among HIV-1-uninfected men and women in east and southern Africa. METHODS: 3399 HIV-1-uninfected women and men from seven countries in east and southern Africa were tested for HSV-2 antibody using the Focus HerpeSelect-2 EIA. The performance of the HerpesSelect-2 EIA was compared with the gold standard HSV-2-specific western blot. RESULTS: Two-thirds (2294/3399) of participants were male and two-thirds (2242/3399) were from east Africa. By western blot testing, HSV-2 prevalence was 68%; 59% in men and 85% in women. At the manufacturer's recommended cut-off value of greater than 1.1, the HerpeSelect-2 EIA had a sensitivity of 98.3% and specificity of 80.3%. Receiver operating characteristic plot analysis indicated that the optimum cut-off was 2.1 or greater, with sensitivity 93.9% and specificity 90.5%. Diagnostic accuracy was modestly higher for southern Africa (area under the curve (AUC) 0.979, 95% CI 0.970 to 0.988) compared with east Africa (AUC 0.954, 95% CI 0.942 to 0.965; p<0.001 for southern vs east Africa). CONCLUSIONS: The Focus HerpeSelect-2 EIA has acceptable diagnostic accuracy for the determination of HSV-2 serostatus in African HIV-1-uninfected adults. An assay cut-off value of 2.1 or greater results in approximately 90% sensitivity and specificity, against a gold standard HSV-2 western blot. Diagnostic accuracy differed slightly by geographical region.
OBJECTIVE: To compare the performance of the Focus HerpeSelect-2 enzyme immunoassay (EIA) with the gold standard herpes simplex virus (HSV) type 2 western blot, among HIV-1-uninfectedmen and women in east and southern Africa. METHODS: 3399 HIV-1-uninfectedwomen and men from seven countries in east and southern Africa were tested for HSV-2 antibody using the Focus HerpeSelect-2 EIA. The performance of the HerpesSelect-2 EIA was compared with the gold standard HSV-2-specific western blot. RESULTS: Two-thirds (2294/3399) of participants were male and two-thirds (2242/3399) were from east Africa. By western blot testing, HSV-2 prevalence was 68%; 59% in men and 85% in women. At the manufacturer's recommended cut-off value of greater than 1.1, the HerpeSelect-2 EIA had a sensitivity of 98.3% and specificity of 80.3%. Receiver operating characteristic plot analysis indicated that the optimum cut-off was 2.1 or greater, with sensitivity 93.9% and specificity 90.5%. Diagnostic accuracy was modestly higher for southern Africa (area under the curve (AUC) 0.979, 95% CI 0.970 to 0.988) compared with east Africa (AUC 0.954, 95% CI 0.942 to 0.965; p<0.001 for southern vs east Africa). CONCLUSIONS: The Focus HerpeSelect-2 EIA has acceptable diagnostic accuracy for the determination of HSV-2 serostatus in African HIV-1-uninfected adults. An assay cut-off value of 2.1 or greater results in approximately 90% sensitivity and specificity, against a gold standard HSV-2 western blot. Diagnostic accuracy differed slightly by geographical region.
Authors: Musa Otieno Ng'ayo; David Friedrich; King K Holmes; Elizabeth Bukusi; Rhoda Ashley Morrow Journal: J Virol Methods Date: 2009-10-23 Impact factor: 2.014
Authors: Samuel Biraro; Philippe Mayaud; Rhoda Ashley Morrow; Heiner Grosskurth; Helen A Weiss Journal: Sex Transm Dis Date: 2011-02 Impact factor: 2.830
Authors: Matthew R Golden; Rhoda Ashley-Morrow; Paul Swenson; Wayne R Hogrefe; H Hunter Handsfield; Anna Wald Journal: Sex Transm Dis Date: 2005-12 Impact factor: 2.830
Authors: J S Smith; R C Bailey; D J Westreich; I Maclean; K Agot; J O Ndinya-Achola; W Hogrefe; R A Morrow; S Moses Journal: Sex Transm Infect Date: 2008-10-27 Impact factor: 3.519
Authors: Oliver Laeyendecker; Charla Henson; Ronald H Gray; Ruby H-N Nguyen; Bobbi Jo Horne; Maria J Wawer; David Serwadda; Noah Kiwanuka; Rhoda Ashley Morrow; Wayne Hogrefe; Thomas C Quinn Journal: J Clin Microbiol Date: 2004-04 Impact factor: 5.948
Authors: Eddy van Dyck; Anne Buvé; Helen A Weiss; Judith R Glynn; David W G Brown; Bénédicte De Deken; John Parry; Richard J Hayes Journal: J Clin Microbiol Date: 2004-07 Impact factor: 5.948
Authors: Edith Nakku-Joloba; Fred Kambugu; Julius Wasubire; Joshua Kimeze; Robert Salata; Jeffrey M Albert; Alfred Rimm; Christopher Whalen Journal: Afr Health Sci Date: 2014-12 Impact factor: 0.927
Authors: Jennifer E Balkus; Lisa E Manhart; Jeannette Lee; Omu Anzala; Joshua Kimani; Jane Schwebke; Juma Shafi; Charles Rivers; Emanuel Kabare; R Scott McClelland Journal: J Infect Dis Date: 2016-02-04 Impact factor: 5.226
Authors: Linnet Masese; Jared M Baeten; Barbra A Richardson; Elizabeth Bukusi; Grace John-Stewart; Susan M Graham; Juma Shafi; James Kiarie; Julie Overbaugh; R Scott McClelland Journal: AIDS Date: 2015-06-01 Impact factor: 4.177
Authors: Erica M Lokken; Barbra A Richardson; John Kinuthia; Khamis Mwinyikai; Amina Abdalla; Walter Jaoko; Kishorchandra Mandaliya; Juma Shafi; R Scott McClelland Journal: Sex Transm Dis Date: 2019-01 Impact factor: 2.830
Authors: R Scott McClelland; Barbra A Richardson; Peter Cherutich; Kishorchandra Mandaliya; Grace John-Stewart; Benard Miregwa; Katherine Odem-Davis; Walter Jaoko; Davies Kimanga; Julie Overbaugh Journal: AIDS Date: 2015-11 Impact factor: 4.177
Authors: Anthony N Muiru; Brandon L Guthrie; Rose Bosire; Michele Merkel; Amy Y Liu; Robert Y Choi; Barbara Lohman-Payne; Ann Gatuguta; Romel D Mackelprang; James N Kiarie; Carey Farquhar Journal: J Infect Dis Date: 2013-07-09 Impact factor: 5.226
Authors: Linnet Masese; Jared M Baeten; Barbra A Richardson; Elizabeth Bukusi; Grace John-Stewart; Walter Jaoko; Juma Shafi; James Kiarie; R Scott McClelland Journal: J Infect Dis Date: 2013-11-22 Impact factor: 5.226